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ABSTRACT
Background: The emergence of the role ofmiaoRNAs (miRNAs) in exacerbating drug resistance oftumours is
recently being highlighted as a crudal research field for future dinical management ofdmg resistant umours.
The purpose ofthis tudywas to identify dys-regulations in expression ofindividual nd/or networks ofmiRNAs
that may have direct effect on neuroblastoma (NB) drug resistance.
Mefhods: Individual subcultures ofchemosensiüve SH-SY5Y and UKF-NB-3 cells were rendered chemoresistant
to doxorubidn (SH-SY5Y, UKF-NB-3) or etoposide (SH-SY5Y). In each validated chemoresistance model, the
parental and subcultured cell lines were analysed for miRNA expression profiling, using a high-throughput
quanütative polymerase chain reaction (RT-qrcR) miRNA profiling platform for a total of 668 miRNAs.
Resulcs: A unique xpression signature of miRNAs was found to be differentially expressed (higher than 2-fold
change) within all three NB chemoresistance models. Four miRNAs were upregulated in the subcultured
chemoresistant cell line. Three miRNAs were found to be downregulated in the chemoresistant cell lines for all
models.
Conclusions: Based on the initial miRNA findings, this study eluddates the dys-regulation offour miRNAs ia
three separate NB chemoresistant cell line models, spanning two cell lines (SH-SY5Y and UKF-NB-3) and two
chemotherapeutic agents (doxorubidn and etoposide). These miRNAs may thus be possibly linked to
chemoresistance induction in NB. Such miRNAs are good candidates to be novel drug targets for future miRNA
based therapies against aggressive tumours that are not responding to conventional chemotherapy,
® 2015 Ayers et al. Published by Elsevier B.V. on behalfofthe Research Network ofComputational and Structural
Biotechnology. This is an open access artide under the CC BY license (http;//creativecommons,org/tlcenses/by/4.0/).
l. Background
Undoubtedly, one of the most frequendy occuiTing malignandes in
childhood is neuroblastoma (NB) [l ], in most cases affecting children
under the age offive [2]. Neuroblastoma isa tumour that develops in
the embiyonic stage [3] and derives from primordial cells of the sympa-
thetic nerveus system known as neural crest cells [4]. These progenitor
cells cease to differentiate and mature, which is the natura! course of
events in neural crest cells en-route to the development of the sympa-
thetic nerveus system in the embryo [5]. The tumourigenesis from
these progenitor cells is thought o be due to the formation of self-
regenerating tumour stem cells that have the ability to produce a dis-
tinct range of different NB cell lineages according to their histology [6|.
The dinical manifestations and degree ofseverity of NB may be high-
ly varied [7]. The initial phase of the condition is the presence of a pain-
less lump on the abdomen, neck or chest of the duld [8]. However, the
tumour usually undergoes metastasis and the child consequently pre-
sents symptoms due to the NB tumour acting as a space-occupying
* Corresponding author.
lesion in the areas of the body that are affected. In order to aid clinicians
and oncologists to determine the severity of NB in the individual patiënt
and consequently implement more bespoke treatment strategies, an
International Neuroblastoma Staging System (INSS) [9] was devised,
based on the degree of NB metastasis and microscopic analysis of the
afflicted tissues of the patiënt This süging system has proved to be of
immense value and is still presently being applied for neuroblastoma
diagnosis.
In overview, patients diagnosed with stage l or 2 NB conditions are
mainly subjected to surgery for exdsing the tumour mass, without the
use of chemotherapeutic cycles or other treatments [10]. However,
patients with stage 3 or 4 NB are at high risk and thus tumour de-
bulking/removal surgery is combined to other treatment strategies
such as chemotherapy (with or without bone marrow transplantation)
and low-dose radiotherapy [10].
Unfortunately, the emergence of chemoresistance within tumour
cells ofsolid tissues is one of the main reasons for treatment failure
and relapse in patients uffering from metastatic cancer conditions [11].
Resistance of the tumour cell to chemotherapeutic agent exposure may
be innate, whereby the genetic characteristics of the tumour cells
are naturally resistant to chemotherapeutic drug exposure [12].
http://dx.doi.org/10,lOIG/J.csbj .2015.04.003
2001-0370/® 2015 Ayers et aL Published by Elsevier B.V. on behalfofthe Research Netwerk ofComputational and Structural Biotechnology. This is an open access artide under the CC BY
license(http://creativecommons.rg/licenses/by/4.0/).
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Altematively, chemoresistance can be acquired through development of
a drug resistant phenotype over a defined time period ofexposure of the
tumour cell to multiple chemotherapy combinations [11,12]. Apart from
other biological and genetic factors influencing the chemoresistance
properties ofsuch tumours, the role ofnon-coding RNAs such as micro
RNAs (miRNAs) [13,14] in the induction ofsuch a phenotype is rapidly
being recognised [15-19].
Within the context of NB, there already exist links between miRNA
dysregulated expression pattems and NB dinical severity [20]. However,
scientific literature provides limited studies relating to the identification
of miRNAs directly contributing to NB chemoresistance, with one of
them being miR-17-Sp [21 ]. This study revealed that he exposure of
chemotherapy resistant NB murine tumour models to antagomirs for
miR-17-5p resulted in an increase in prognosis, due to enhanced apo-
ptosis and cell cycle arrest effects [21 ]. In addition, miR-21 is a known
oncomir and was found to be over-expressed in cisplatin resistant NB
cell lines [22]. Another study has also identified miR-204 as a potentiaUy
important miRNA that conveys suppressive properties against he
chemoresistance phenotype in NB [23].
2. Methodology
The purpose ofthis tudywas to identifyand validate (ifany) spedf-
ic miRNAs that could be directly involved in the exacerbation of
chemoresistance properties in NB cell lines. The utilisation ofRT-qPCR
based miRNA profiling can nowadays be employed for serving such
research objectives.
2,1. Description of NB cell line chemoresistance modek
Eight separate NB cell line models were ünplemented in this study.
Each model consisted oftwo cell lines, a parental chemosensitive to-
gether with a sub<ultured cell line that was rendered chemoresistant
to a single conventional chemotherapeutic agent hrough repeated
exposure (see Table 1).
22. Validatwn ofchemosensitivity status for NB ceü lines
Prior to miRNA profiling of all NB cell lines, validation of their
chemosensitivity stams was paramount o ensure that the subcultured
chemoresistant cell line in each model retained its drug resistance prop-
erties over several culturing passages without fürther drug exposure.
The method adopted forvalidating chemoresistance status in each
model consisted ofluminescence-based cell viability analysis, through
the utilisation of the Cell Titer Glo assay [Promega, USA] on a Fluorostar
Optima luminescence plate reader platform [BMG, Germany], according
to the manufacturer's protocol. Due care was applied in maintaining a
seeding cell population across all culture wells utilised in the functional
assay, in order to avoid false positive viability readings.
Tabtel
Ust of NB chemoresistance cell line models. Subcultures ofeach parental
cell line were induced to acquire chemoresistance properties towards a
single chemotherapeutic agent The SH-SY5Y and Kelly cell lines were
obtained from the Eggert group, Essen, Germany. The UKF-NB-3 cell
lines were obtained from the Gnatljr group, Frankfurt, Germany.
NB ceiï line Chemotherapeutic agent
SH-SY5Y
SH-SY5Y
SH-SY5Y
KELLY
KELLY
KELLY
UKF-NB-3
UKF-NB-3
Cisplaön
Doxorubidn
Etoposide
Cisplatin
Doxorubidn
Etoposide
Doxorubidn
Vincristine
22.1. Cell culturing conditions and harvesüng
The growth medium utilised for culturing of all cell ines in this study
consisted ofRPMl 1640 [Gibco, USA] treated with 10% foetal calfsemm
[Gibco, USA] and 1% by volume of 1:1 penicillin/streptomycin mix
10,000 U/mL, kanamicin 10 mg/mL and L-glutamate 200 mM [Gibco,
USA] respectively. Prior to a three-minute step within T25 cell culturing
Hasks [Coming, USA], versene solution [Gibco, USA] was used for wash-
ing all adherent cells within the culture flasks. The trypsin solution
utilised consisted of 0.05% trypsin with EDTA [Cibco, USA]. Harvesting
of cell suspensions for RNA extraction was performed by adding
0.7 mL Qiazol solution [Qiagen, Germany],
222. NB chemoresistance model cell viabiüty assay
For each chemoresistance model investigated in this study, both the
parental chemosensitive and subcultured chemoresistant NB cell lines
were grown in culture and simultaneously harvested and transferred
to a sterile 50 mL tube [BD Bioscience, USA]. The cell population density
for each cell ine was counted by extraction of a 20 pL sample (following
vigorous pipette mixing) and analysed on a Cellometer Auto T4 cell
counter platform [Nexcelom Bioscience, USA] according to
manufacturer's protocol. Both cell cultures where then diluted as neces-
sary with sufficient growth medium to produce a cell culture with a cell
population density ofapproximately 10,000 cells/95 pL Consequently,
95 pL aliquots from each cell line were transferred (following vigorous
pipette nuxing) to an opaque Nunclon 96 well microtitre plate [Nunc,
USA].
For each cell line, 18 wells were utilised for consequent drug treat-
ment, and nine wells were to serve as non-ü-eated NB negative controls
(NB cell culture only, with no drug exposure). A further SK wells were
treated with 195 pL growth medium only, in order to act as negative
controls (drug exposure only). All remaining wells were treated with
200 pL growth medium. Finally, the microtitre plate was placed in an
incubator at 37 °C and 5% CÖ2 for 24 h, to allow cell adhesion on well
surface.
Following the 24-hour incubation, the microtio'e plate containing
adherent cells was retrieved and treated with the appropriate chemo-
therapeutic agents for each chemoresistance l] line model. The vary-
ing drug dilutions (see Table 2) were prepared on the same day when
used for treatment, using filter sterilised water [Sigma, USA] within
the confines of a Class II laminar flow cabinet AU light sensitive drug
diludons were also covered in aluminium foil until required.
Once retrieved from the incubator, the plate was placed inside a
laminar flow cabinet and all wells designated for treatment with the
appropriate chemotherapeutic agent were exposed. A 5 pL aliquot of
the appropriate drug and dose was pipetted, following vigorous pipette
mixing of the drug solution, into the appropriate triplicate wells. An
extra 5 pL aliquot ofeach dmg dose was applied to a single well contain-
ing only growth medium, in order to obtain background luminescence
data from a drug/growth medium solution for future use following
cell viability analysis. The plate was then re-incubated for a fürther 36 h.
Following this time period, the plate was collected and a cell viability
assay was performed on all wells, by using the Cell Titer Glo assay
[Promega, USA] according to manufacturer's protocol.
Table2
Chemotherapeutic drug ranges utilised for investigating chemosensitivity status in each
cell line. AU treatments were performed in triplicate for each dmg dose.
Chemotherapeutic Drug dose range (ng/mL)
Plate row location Cisplatin Doxorubidn Etoposide Vincri5tine
50,000
5000
500
50
5
0.5
28,993
2899.9
289.99
28.999
2.9
0.29
1,000,000
100,000
10,000
1000
100
10
4615
461.5
46.15
4.615
0.465
0.046
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22.3. Data anatysis and statistical analysis
Followüig the assay, the Excel sheet containing all raw luminescence
data was collected for analysis, with outliers being identified and
discarded. The chemosensitivity profiles, based on the cell viability anal-
ysis data set results, were plotted by application of the Graph Pad Prism
software package [GraphPad Software Inc., USA], No detaüed statistical
analysis was performed on the resultant data sets as long as the
inhibiting concentration for 50% cell viability (1C50) demonstrated
distinct values, reflecting the chemosensitivity profiles.
23. NB ceU line miRNA profiling
23.1. Ceü line harvesting and lysis
All cell lines from each validated NB chemoresistance model were
cultureel and harvested accordingly. Following trypsin incubation step,
each T25 flask was subjected to horizontal mechanical shock, necessary
for dislodging all cells from the flask surface. The resultant cell suspen-
sion from each flask was transferred to an individually labelled, sterile
15 mL collection tube [BD Biosciences, USA] and centrifuged at
1500 rpm for five minutes to allow all cells to fonn a pellet at the base
of the collection tube. The supematant from each collection tube was
aspirated by disposable, sterile glass pipette with due care to avoid
inadvertent aspiration ofcell pellet Consequently, the remaining cell
pellet was treated with 700 pL of Qjazol solution [Qjagen, Germany] in
order to induce cell lysis. This step was performed within the confines
of a füme cupboard and thorough pipette-müeing was applied for ensur-
ing a resultant homogenous cell lysate suspension. Immediately after
cell lysis induction, all cell lysate suspensions were snap frozen in liquid
nitrogen solution and transferred to a - 80 °C freezer until RNA extrac-
tion was performed.
2-3.2. miRNA extraction procedure
All NB cell line lysates were allowed to thaw to room temperature
prior to miRNA extraction. Consequently, all lysates were treated with
the miRNeasy [Qjagen, Cermany] miRNA extraction protocol, within
the confines of a füme cupboard. The resultant 30 |JL volume ofextract-
ed miRNA from each NB cell line lysate was quantified through
utilisation of the Nanodrop UV spectrophotometry platform [Nanodrop
Technologies, USA]. The extracted miRNA samples were then stored at
-80 °C until further use. The RNA quality was not tested following
extraction, as previous experience from earlier studies repeatedly
demonstrated that the RNA quality derived from NB cell lines was
always ofan excellent nature (with RIN values above 9.0), thus such a
step was not perfbrmed.
23.3. RT-qPCR based miRNA profilmg
All miRNA samples were allowed to thaw prior to further treat-
ments. The protocol utilised in this step was a validated, high through-
put RT-qPCR based miRNA profiling method [30]. In summary, miRNA
samples were diluted to a standardised concentration and initially sub-
jected to a megaplex reverse transcription protocol [30]. This was
followed by a pre-amplification step and eventual qPCR analysis [30].
23.4. Data normafaation and analysis
All raw Cq values obtained from each individual run were corrected
by inter-run calibrators (five individual small nucleic RNA assays -
RNU24, RNU44, RNU48, RNU6B, U6 snRNA; two technical replicates/
assay/plate) and consequendy normalised against he average Cq value
obtained from the total quantity ofmiRNAs assayed within the same
run [27]. The normalised Cq expression data for each miRNA was com-
pared between the constituent chemosensitive and chemoresistant cell
lines for each chemoresistance model. All miRNAs found to be dysregu-
lated within the chemoresistant cell line, following the adoption of a
+/- 2x linear fold change cut-offvalue, were deemed to be putative
chemoresistance miRNAs within the individual chemoresistance
model. This nominal cut-offvalue issubjective and was deemed to be
acceptable to attain a legitimate shon list ofmiRNAs having a tangible
expression dysregulation profile of sufficient weight as to lead to an
overall shift in chemosensitivity profile (in this case, see Discusslon
section).
Ultimately, all miRNAs dysregulated in all three chemoresistance
models' miRNA shortlists were identified and selected for further
investigation.
2-3.5, Multiplex RT-qPCRforputative chemoresistance miRNAs
The putative miRNAs identified from miRNA profiling to be dysreg-
ulated in the chemoresistant cell lines were further analysed by multi-
plex RT-qPCR.
Taqman miRNA RT kit [ABI, USA] was utilised for the reverse tran-
scription step. Reverse transcriptase (RT) primers pecific for the rele-
vant target miRNAs [ABI, USA] were diluted (5 nmol) with 250 \iL
nudease free water [Sigma, USA], and 10 pL aliquots from each individ-
ual primer solution were pooled in a l .5 mL Eppendorf tube. The primer
pool was then diluted with nuclease free water or concentrated by
vacuüm centrifugation i order to obtain a final volume equivalent to
20% of the total RT reaction volume utilised in this step. The RT reaction
volume (per well) consisted of4|jL stem-loop primer pool, 0.4 pL of
lOELLY / DCaXORUBiaN
Control -10123466
Doxorubicin Doe» (tog n^rrL)
KBULY/OSPIATIN
Gortrol -101234
Cisp|gtinDo6e(k>gn9'iTL)
KEU-Y/ETOPC381DE
Cartrol -10 1 2 3 4 S 6
Etopoekto DOM <tog nfl'nl.)
Fig. l. Results for cell viabiUty analysis ofKelly NB chemoresistance models (n = l, three
tedmical replicates/data point, SEM not illustrated). In all three assays the chemosensiüvity
status for each component NB ceU line was not suitable for inclusion in the miRNA profiling
study (black - chemosensitive parental NB cel] line; red - chemoresistant NB cell line).
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100 nM dNTPs, 4 |jL MultiScribe reverse transcriptase [Applied
Biosystems, USA], 2 |jL of 10 x RT buffer, 0.25 |jL RNase inhibitor [Applied
Biosystems, USA] and 0.65 pL nuclease free water. The total reaction
volume was then placed in a thermal cycler and subjected to 30 min
at a temperature of 16 °C, followed by 30 min at 42 °C, l s at 50 °C,
5 min at 85 °C and 5 min at 4 °C respectively. The finalised reaction
volume was diluted by a factor of five, prior to RT-qKR step.
The TaqMan® miRNA assay for RT-qPCR quantification was utilised
in this step for all miRNA assays. Assays for hsa-mir-99b, hsa-mir-
125a and hsa-mir-425 were also prepared as reference miRNAs for
post-run data normalisation and analysis. All miRNA assays for each
cell line sample cDNA were performed in triplicate, with water -
cöntaining negative controls. The reaction volume (per well) contained
2.5 pLTaqMan Master mix, 0.125 ^  TaqMan miRNA probe and primers,
2 pL of sample cDNA and 0.375 pL nuclease free water. The cycling
protocol was run on the AB1 7900HT qPCR platform [ABI, USA] and
consisted ofan initial holding stage of 95 °C for 10 min, followed by
40 cycles of 95 °C for 15 s/60 °C for l min, ending with a final holding
stage of 37 "C for 5 min. Following the qPCR run, the data was exported
and analysed, including statistical analysis, on the qBasePIus oftware
package [Biogazelle, Belgium].
3. Results
3.1. Validation ofchemosensitivity status for NB cell lines
Prior to performing miRNA profiling for each individual cell line
within the vaiying NB chemoresistance models, it was essential to con-
firm the chemosensitivity profiles. This was implemented by performing
a luminescence based cel) viability assay, following a pre-detennined
exposure period by the cell lines to the relevant chemotherapeutic
agent. However, the luminescence detection platform also required
prelüninary analysis to confirm optimum performance.
From the eight NB chemoresistance cell line models available, cell
viability analyses only confirmed three models to still have the necessary
chemosensitvity profiles required for investigating miRNA expression
profiling (see Figs, 1-4). The three validated models (SH-SY5Y/ETOPO,
SH-SY5Y/DOXO, UKF-NB-3/DOXO) were analysed by two individual
cell viability assays to ensure chemosensitivity profiles.
Each NB chemoresistance cell line model was analysed to confirm
chemosensitivity status ofits constiment cell lines. The cell lines that
confirmed chemosensitivity status were re-analysed with a second,
identical cell viability analysis in order to ascertain such status prior to
miRNA profiling.
Following the set ofcell viability assays on each NB chemoresistance
model, only three out of the initial eight cell line models were confinned
to have maintained their chemosensitivity profiles, namely the SH-
SY5Y/DOXO, SH-SY5Y/ETOPO and UKF-NB-3/DOXO NB chemoresistance
models. The extracted RNA from constituent cell lines, from each of the
three cell line models, were consequendy eligible for miRNA profiling.
32. NB ceü line miRNA profiling
The expression profiling of 668 miRNAs for each constituent cell line
of the three validated and selected NB chemoresistance ll line models
demonstrated that approximately 50% of all miRNAs are expressed
above the 35 Cq value (see Figs. 5-7). Additionally, the expression
scatterplot profiles highlight hat overall miRNA expression is cell line
dependent
The results of the miRNA expression profiling revealed that a
putative chemoresistance signature xpression ofseven miRNAs was
present in all three NB chemoresistance ll line models (see Fig. 8).
UKF-hB-3 /DOXORUBldN UKF.N&3 / ^ NCWSnrE
Control .1012346
Doxorubicin Dose (log ng'nt.)
WF-NB-31 DQXORUBIQN
(2ndRun)
Cortrol -10 1 2 3 4 S
Vinertetirw Dose (log n@'rrL)
LKF.NB-3 / VINCWST^
(2-ndRun)
Ccrtrol -1012345
Doxorubiein Das» (ksg r^rrt.)
Contra; 012343
VhwiBtlrw Dei» (kas ng/mL)
Fig. 2. Results for cell viabflity analysis ofUKF-NB-3 NB chemoresistance models (two separate runs, n = l, three technical repUcates/data point, SEM not illustrated). Tlie doxombidn
chemoresistance model was included in the miRNA profiling study due to a 10-fold linear change in the 1C50 dose for both constitutive cell lines. However, at elevated doxorubidn
doses a reprodudble, artificial increase in cell viability was noticed within this NB chemoresistmce model. The UKF-NB-3/vincristine NB chemoresistance model was not induded in
the study due to incongruent chemosensitivity profiles for each constituent NB cell ine (black - chemosensiüve parental NB cell ine; red - chemoresistant NB cell ine).
D. Ayers et ai / Computational and StructuralBwtechmlogyJoiimal 13 (2015) 307-319 311
a+©Y5Y pLNCX / DOKORUBiaN
. S+SVSYpinrtsl
* SH-SWYDoMaztein
reststert
SH^YSY pLNGX /OOXORUBiaN
(2ndRun)
Cortrol
Doxoruücjn Dos» (tog n£^rri-)
SHSY5Y pLNCX /OSPLATIN
. SM-SYSYpsreTld
SH-SYSY Qsplafn resistmt
Cortrot -10123456
Cisplatin Ros» (tog ng'irt-)
SHSY5Y pLNGX / BTOPCSire
SHSVSYpErertd
SH.SY5Y Bcpcsida rasstNlt
Ccnbd .1012345
Etopow*» Desa (tog n^rrtj
Fig. 3. Results for cell viability analysis of SH-SY5Y NB chemoresistance models (n = l,
three technical replicates/data point, SEM not illustrated). The dsplatin chemoresistance
NB model was not included in the study due to lack ofasuitable chemosensitivity profile
by the predicted chemoresistant NB cell line component for this model.
All seven miRNAs were consequenüy selected for validation ofexpres-
sion by multiplex RT-qPCR miRNA assay, prior to proceeding to
chemoresistance fünction validation assays.
All identified miRNAs deemed to be involved in NB chemoresistance
were consequently eligible for downstream validation studies.
33. MultiplexKT-qPCRforputative chemoresistance miRNAs
Once the short list ofputative chemoresistance miRNAs was eluddat-
ed, it was deemed necessaiy to validate such findings by re-confimiing
the degree of dysregulated expression of each individual putative
miRNA.
Since the miRNA profiling step did not utilise technical replicates for
each individual miRNA RT-qPCR assay (one replicate/miRNA), itwas
essential to re-confirm the dysregulated expression status for each
individual putative NB chemoresistance miRNA within each constitu-
tive NB cell line ofeach chemoresistance model uülised in this study.
This was implemented by performing a secondary RT-qPCR assay,
with three technical replicates for each miRNA assay, in order to ascer-
tain the specific miRNA expression levels.
Following re-analysis of RNA from each of the three NB
chemoresistance models' cell line constituents by multiplex RT-qPCR
miRNA assay, only four out of the original seven-member putative
SH.SVSYpmrtd
a+SvïY DoMsaüeln rwistent
Cortrol .1012348
DoKorufafoin Dose (tog n^nt)
SHSY5Y pUNCX/ ETOPOSIDE
(Zndrun)
. SH-SYSYFwentsl
* SH-SYSyEtoposidereslstErt
ConW .101 23 4 S 6
Boposkte Desa (tog r^rrL)
Fig. 4. Cell viability analysis results (2nd run, n = 1, three technical replicates/data point,
SEM not illustrated) for re-confirmation fchemosensitivity profiles for each constituent
NB cell line chemoresistance model.
chemoresistance miRNA signature werc pursued for fünctional validation
(seeFigs. 9-15).
4. Discussion
Initial performance results of the luminescence reader platform
proved to be successfül in achieving specifidty ofluminescence analysis,
with a standard deviation of approximately 1%. Additionally, the
dynamic range of the luminescence platform was also deemed optimal,
with the lower end of the platform sensitivity spectrum denoted at a cell
suspension density of 12,500 cells/mL
From the eight NB chemoresistance cell line models at disposal
in-house, only three models (SH-SY5Y/ETOPO, SH-SY5Y/DOXO and
UKF-NB-3/DOXO) demonstrated istinct chemosensitivity profiles for
the constitutive cell lines.
Analysis of the three Kelly NB chemoresistance models highlighted
incongruendes in the chemosensitivity profiles of the component cell
lines and was therefore excluded from the study.
For the UKF-NB-3 chemoresistance models, the UKF-NB-3/vincristine
model was also excluded due to inability to confirm the projected
chemosensitivity profiles for the two component cell lines, over two
separate cell viability assays post-vincristine xposure. However, the
UKF-NB-3/DOXO cell line reproducibly demonstrated to confirm the
predicted chemosensitivity profiles, with the doxorubicin-resistant
component cell line proving to be resistant o the drug exposure dose
on comparison with the chemosensitive counterpart cel! line by a factor
of ten, on comparing the doxorubicin doses required to induce 50%
decrease in cell viability. A peculiar observation was also denoted with-
in the UKF-NB-3/DOXO model, in that at the elevated doxorubidn doses
the cell viability in both component cel] lines seems enhanced. This
observation was found to be reproducible across two separate cell
viability assays and was solely noticed within this specific NB
chemoresistance model (UKF-NB-3 cell line exposed to doxorubicin).
Possible explanations for such an anomaly would be technical interfer-
ence with the luminescence assay, though the actual source thought to
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Fig. 11. Multiplex RT-qPCRassay results (log-fold change) for hsa-miR-188-5p following normalisation with reference miRNAs. Expected up-regulation ofputative miRNAwas confirmed
in all three NB chemoresistance models. Error bars represent standard eviation. Assays for hsa-mir-99b. hsa-mir-125a and hsa-mir-425 were also prepared as reference miRNAs for
opost-run data normalisation and analysis.
properties, thus giving the clinician an accurate picture of the clinical
manifestation in the individual child suffering from NB. Following
miRNA profiling and consequent fünctional assay validation techniques
described above, the results are still incondusive regarding adopting the
seven-miRNA signature as hallmark biomarkers for NB chemoresistance.
The results from the KT-qPCR study ofoncogene over-expression on MDR
gene dysregulation also proved to be inconclusive. Therefore, future
studies such as the experimental designs suggested for future research
described above might help to identify other miRNAs with more reliable
and robust validation assay results to confirm their involvement in the
induction of NB chemoresistance properties. Such identified miRNAs
would ultimately be udlised in the clinical setting for diagnostic purposes
to recognise NB tumours having chemoresistance properties to conven-
tional chemotherapeutic agents.
Similar diagnostic screens have already been designed for accurate
diagnosis of other severe conditions uch as human papilloma viral
infectious trains, though such bespoke microarray technology could
be implemented for the recognition of specific miRNA sequences
present in any clinical sample [33]. For NB diagnostic purposes,
identification of novel biomarkers may also be attained through the
profiling of other classes such as long non-coding RNA molecules
(utilising RT-qPCR), whole genome microarray profiling and also
exome next-generation sequenang.
However, the validation methods for confirming individual candi-
date biomarkers may be time consuming. This is a particular problem
for exome sequencing approaches, due to the vast array of data that is
commonly generated and thus requires thorough bioinformatic analysis
prior to even identifying candidate xome sequence biomarkers for
consequent validation assays. In distinct contrast, he possibility ofiden-
tifying navel body fluid biomarkers, uch as free-drculating miRNAs
[34], ultimately provides an extremely rapid diagnostic/prediction test
within the clinical setting due to the sole requirement of a blood sample
for RT-qPCR analysis. However, biomarker validation techniques
are very much dependant on the specific phenotype with which the
individual candidate biomarker needs to be reliably linked to (e.g.
chemoresistance, cell proliferation, cell differentiation).
For the validation of miRNAs associated with chemoresistance,
transient transfection of miRNA antagonists remains the mainstay
l'
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Fig. 12. Multiplex RT-qPCR assay resuta (log-fold chmge) for hsa-miR-204 foUowing normalisation with reference miRNAs. Expected down-regulation of putative miRNA was solely
confirmed in UKF-NB-3/DOXO NB model. Error bars represent standard eviation. Assays for hsa-mir-99b, hsa-mir-125a and hsa-mir-425 were also prepared as reference miRNAs for
post-run data normalisation and analysis.
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Fig. 15. Multiplex RT-qPCR assay results (log-fold change) for hsa-miR-769-3p following normalisation with reference miRNAs. Expected own-regulation fputative miRNA was not
confirmed in all three chennoresistance models. Error bars represent standard eviation. Assays for hsa-nnir-99b, hsa-mir-125a and hsa-mir-425 were also prepared as reference miRNAs
for post-nm data normalisation and analysis,
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